We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Tiny Needles Reshape Major Eye Disease Treatment

By HospiMedica International staff writers
Posted on 23 Nov 2014
Print article
Image: Solid microneedles coated with Bevacizumab (syringe for scale) (Photo courtesy of the Georgia Institute of Technology).
Image: Solid microneedles coated with Bevacizumab (syringe for scale) (Photo courtesy of the Georgia Institute of Technology).
Novel microneedles allow dramatic dose sparing when compared to subconjunctival and topical administration of drugs directly into the eye.

Developed by researchers at the Georgia Institute of Technology (GATech; Atlanta, USA) and Emory University (Atlanta, GA, USA), the microneedles, which range in length from 400 to 700 micrometers, could provide a new way to deliver drugs to specific areas within the eye relevant to glaucoma and corneal neovascularization, two of the world’s leading eye diseases. By targeting the drugs to specific parts of the eye instead of the entire eye, researchers hope to increase effectiveness, limit side effects, and reduce the amount of drug needed.

To treat glaucoma, the stainless steel microneedles were designed to penetrate through the sclera (the outer layer of the eye), to the supraciliary space located near the ciliary body, which produces the aqueous humor. The chosen drug is also formulated with increased viscosity to retain it near the injection site and provide a controlled release of the therapeutic compounds. And because the injection targets drug delivery, just one percent of the amount of drug is required to produce a similar decline, as compared to eye drops.

To treat corneal neovascularization, the researchers took a different approach, coating solid microneedles with Bevacizumab, an antibody-based drug that prevents blood vessel growth. They inserted the coated needles near the point of an injury, keeping them in place for approximately one minute until the drug dissolved into the cornea. In an animal model, placement of Bevacizumab halted growth of unwanted blood vessels for two weeks after just a single application. The study describing the new microneedles was published on November 13, 2014, in Investigative Ophthalmology & Visual Science.

“The power of microneedles for treating eye conditions is the ability to target delivery of the drug within the eye,” said lead author Prof. Mark Prausnitz, PhD, of the school of chemical and biomolecular engineering at GATech. “We are developing different microneedle-based systems that can put the drug precisely into the part of the eye where it’s needed. In many cases, we hope to couple that delivery with a controlled-release formulation that would allow one application to treat a condition for weeks or months.”

Related Links:

Georgia Institute of Technology
Emory University


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Needlefree Closed System Transfer Device
ChemoClave

Print article

Channels

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.